References
- Brandt J, Dietrich S, Meissner J, et al. Quality of life of long term survivors with Hodgkin's lymphoma after high-dose chemotherapy, autologous stem cell transplantation and conventional chemotherapy. Leuk Lymphoma 2010;51:2012–2020.
- Josting A, Sieniawski M, Glossmann JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005;16:1359–1365.
- van Besien K. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma 2006;47:1447–1448.
- Heutte N, Flechtner HH, Mounier N, et al. Quality of life after successful treatment of early-stageHodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial. Lancet Oncol 2009;10:1160–1170.
- van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long-term survivors of Hodgkin's disease. Ann Oncol 1994;5:153–158.
- Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999;23:1131–1138.